Ilyang Pharm’s ‘Prion Treatment Development’ selection as study supported by MOHW

The Ilyang Pharm’s(CEO Dong-Yeon Kim) development of prion treatment has recently been selected as the ‘Development of Technology to Overcome Diseases Transmitted Cross-species to Humans’ by the Ministry of Health and Welfare(MOHW).

Ilyang Pharm has conducted a broad-scale research with the most notable research institute for the field of prion in Korea ‘Hallym University Ilsong Institute of L...